Hypothesis corpus
Scored, debated, and tradable. Each hypothesis carries composite, novelty, impact, mechanistic, druggability, and safety scores — plus a live market price when a collider is open.
Showing metabolomics hypotheses, sorted by Composite score.
NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Metabolic Catastrophe
PARP1, SIRT1/3, NAD+ metabolomics 55%53% posterior · 1 signalPostmortem AD hippocampus shows 60-70% reduction in NAD+ concentration with corresponding PARP1 hyperactivation
h-ab3a0af5Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation
SLC16A1 (MCT1) metabolomics 46%60% posterior · 4 signalsHuman AD prefrontal cortex shows 40-60% reduction in MCT1 and MCT4 protein expression compared to age-matched controls
h-40d0524fBranched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis
BCAT1/BCAT2 metabolomics 40%47% posterior · 1 signalMetabolomic studies report elevated plasma BCAAs in AD patients, with decreased utilization in brain tissue
h-8e4e15dcApolipoprotein E4-Mediated Metabolic Dysfunction Correction via Liver X Receptor Agonism
NR1H2 (LXRβ), APOE metabolomics 38%ApoE4 knock-in mice exhibit accumulation of neutral lipids and cholesterol esters in astrocytes, with impaired lipid efflux
h-24f6280dCD38 Inhibition to Prevent NAD+ Depletion and Restore Cellular Bioenergetics in Age-Related Metabolic Dysfunction
CD38, SIRT1/3 metabolomics 38%Postmortem AD hippocampus shows 60-70% reduction in NAD+ concentration with corresponding PARP1 hyperactivation
h-var-f40275ceb0NAD+-Dependent Upregulation of MCT1 Expression to Restore Neuronal Ketone Metabolism
SLC16A1 (MCT1) metabolomics 38%Postmortem AD hippocampus shows 60-70% reduction in NAD+ concentration with corresponding PARP1 hyperactivation
h-var-ffacbbd9f1Enhancement of Astrocytic Ketone Body Production via HMGCS2 Overexpression
HMGCS2 metabolomics 38%47% posterior · 1 signalHuman AD prefrontal cortex shows 40-60% reduction in MCT1 and MCT4 protein expression compared to age-matched controls
h-var-4bd74ce5ceEnhancement of Astrocytic Ketone Body Production via HMGCS2 Overexpression
HMGCS2 metabolomics 38%47% posterior · 1 signalHuman AD prefrontal cortex shows 40-60% reduction in MCT1 and MCT4 protein expression compared to age-matched controls
h-var-7b45fa04f3NAD+-Dependent Transcriptional Upregulation of MCT1 to Restore Neuronal Ketone Metabolism
SLC16A1 (MCT1) metabolomics 38%Postmortem AD hippocampus shows 60-70% reduction in NAD+ concentration with corresponding PARP1 hyperactivation
h-var-cbd9922117CD38 Inhibition to Preserve NAD+ Pools and Prevent PARP1-Mediated Metabolic Dysfunction
CD38, PARP1, SIRT1/3 metabolomics 38%47% posterior · 1 signalPostmortem AD hippocampus shows 60-70% reduction in NAD+ concentration with corresponding PARP1 hyperactivation
h-var-de3e3c7494Mitochondrial Pyruvate Carrier Inhibition to Force Metabolic Reprogramming Toward Ketone Utilization
MPC1/MPC2 metabolomics 35%MPC1 mRNA upregulation in human AD brain (computational: GTEx Brain Tissue Expression Database)
h-4a4a2713Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacological Activation of Monocarboxylate Transporters
SLC16A3 (MCT4) metabolomics 31%47% posterior · 1 signalMetabolomic profiling of AD vs. control prefrontal cortex reveals significantly elevated lactate/creatine ratio in affected regions
h-4e806018Blood-Brain Barrier Metabolite Transporter Enhancement for Diagnostic and Therapeutic Dual Benefit
SLCO2A1 (OATP2A1) metabolomics 27%55% posterior · 3 signalseQTL analysis reveals common variants in SLCO2A1 associated with altered BBB permeability in aging (GTEx v8)
h-b53bbd76